Drug Approval | June 24, 2022
Rivaroxaban approved in Japan for patients with PAD after revascularisation
It´s the first trial to demonstrate the benefits of dual pathway inhibition
It´s the first trial to demonstrate the benefits of dual pathway inhibition
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
Bringing next-gen cannabinoid therapeutics to cancer patients
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Expanding diagnostics footprint in East India
The three-year collaboration will focus on the development of new tools for computational chemistry modelling as well as new molecular representations to advance the next generation of molecular machine learning
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Subscribe To Our Newsletter & Stay Updated
